JPH11507352A5 - - Google Patents

Info

Publication number
JPH11507352A5
JPH11507352A5 JP1997501850A JP50185097A JPH11507352A5 JP H11507352 A5 JPH11507352 A5 JP H11507352A5 JP 1997501850 A JP1997501850 A JP 1997501850A JP 50185097 A JP50185097 A JP 50185097A JP H11507352 A5 JPH11507352 A5 JP H11507352A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997501850A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11507352A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1996/009553 external-priority patent/WO1996040726A1/en
Publication of JPH11507352A publication Critical patent/JPH11507352A/ja
Publication of JPH11507352A5 publication Critical patent/JPH11507352A5/ja
Withdrawn legal-status Critical Current

Links

JP9501850A 1995-06-07 1996-06-05 新規カルバメート基本カチオン性脂質 Withdrawn JPH11507352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48346595A 1995-06-07 1995-06-07
US08/483,465 1995-06-07
PCT/US1996/009553 WO1996040726A1 (en) 1995-06-07 1996-06-05 Novel carbamate-based cationic lipids

Publications (2)

Publication Number Publication Date
JPH11507352A JPH11507352A (ja) 1999-06-29
JPH11507352A5 true JPH11507352A5 (enExample) 2004-07-29

Family

ID=23920143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9501850A Withdrawn JPH11507352A (ja) 1995-06-07 1996-06-05 新規カルバメート基本カチオン性脂質

Country Status (6)

Country Link
US (2) US6251939B1 (enExample)
EP (1) EP0830368A1 (enExample)
JP (1) JPH11507352A (enExample)
AU (1) AU701106B2 (enExample)
CA (1) CA2223088A1 (enExample)
WO (1) WO1996040726A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958901A (en) * 1995-06-07 1999-09-28 Genta Incorporated Phosphonic acid-based cationic lipids
JP4340330B2 (ja) * 1996-05-24 2009-10-07 アイシー‐ヴェック・リミテッド トランスフェクション剤としてのポリカチオン性ステロール誘導体
WO2004089973A2 (en) * 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
FR2760193B1 (fr) * 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
US5877220A (en) * 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
US6034135A (en) * 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
CA2299429C (en) 1997-08-13 2010-04-20 Biontex Laboratories Gmbh New lipopolyamines,their preparation and the use thereof
CA2395636A1 (en) * 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
GB0015624D0 (en) * 2000-06-26 2000-08-16 Nat Cancer Centre Materials and methods relating to improved gene delivery
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US20040161741A1 (en) * 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
KR20050039700A (ko) * 2001-10-25 2005-04-29 아테로제닉스, 인코포레이티드 이식거부 치료용 화합물 및 치료 방법
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
AU2004272646B2 (en) * 2003-09-15 2011-11-24 Arbutus Biopharma Corporation Polyethyleneglycol-modified lipid compounds and uses thereof
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
CA2710713C (en) * 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
EP2224912B1 (en) * 2008-01-02 2016-05-11 TEKMIRA Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
JP5475753B2 (ja) 2008-04-15 2014-04-16 プロチバ バイオセラピューティクス インコーポレイティッド 核酸送達用の脂質製剤
EP2326331A4 (en) * 2008-08-18 2013-05-15 Merck Sharp & Dohme NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
CA2743139C (en) 2008-11-10 2019-04-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
EP2405921A4 (en) 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc COMPOSITIONS AND METHODS FOR INACTIVATION OF APOLIPOPROTEIN C-III EXPRESSION
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011011447A1 (en) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus gene expression
AU2010328336B2 (en) * 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8455455B1 (en) 2010-03-31 2013-06-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes involved in hemorrhagic fever
US9254327B2 (en) 2010-05-10 2016-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US10077232B2 (en) * 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
EP2569276B1 (en) * 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Novel cationic lipids and methods of use thereof
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP4295895A3 (en) 2017-05-11 2024-03-27 Tc1 Llc Thermal interconnect for implantable blood pump
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
AU2023249179A1 (en) * 2022-04-05 2024-09-26 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
AU2023275780A1 (en) 2022-05-25 2024-12-05 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3649674A (en) * 1967-08-25 1972-03-14 Schering Ag Salts of carbamic and thiocarbamic esters with fungicidal and fungistatic action
US4007281A (en) * 1971-04-16 1977-02-08 Colgate-Palmolive Company Pharmaceutical compositions containing quaternary ammonium compounds
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1252778A (en) * 1983-08-25 1989-04-18 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Steroids
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1268404A (en) 1985-03-15 1990-05-01 Antivirals Inc. Polynucleotide assay reagent and method
ATE222602T1 (de) 1985-09-12 2002-09-15 Scios Inc Rekombinante fibroblasten-wachstums-faktoren
JP3134874B2 (ja) 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Ｔ細胞表面タンパク質ｔ４をコードするｄｎａ並びにｔ４フラグメントのａｉｄｓ治療への使用
KR890701605A (ko) 1987-07-04 1989-12-21 원본미기재 Dna 서열, 재조합 dna 분자 및 용해성 t4 단백질의 제조방법
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
JPH03504496A (ja) * 1988-04-08 1991-10-03 スクリプス　クリニック　アンド　リサーチ　ファウンデーション 水素結合の共有結合置換により安定化されたポリペプチド
JP2826826B2 (ja) * 1988-04-11 1998-11-18 日本ケミファ株式会社 アルキレンジアミン誘導体
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US4936868A (en) * 1988-07-29 1990-06-26 Shell Oil Company Fuel composition
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
CA2058632C (en) 1989-06-05 2004-08-24 Brian C. Froehler Exonuclease-resistant oligonucleotides and methods for preparing the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
EP0498843B1 (en) 1989-10-24 1996-06-12 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
DE69034150T2 (de) 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
CA2083719A1 (en) 1990-05-25 1991-11-26 Mark D. Matteucci "sequence-specific non-photoactivated crosslinking agents which bind to the major groove of duplex dna
WO1992002258A1 (en) 1990-07-27 1992-02-20 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
WO1992009705A1 (en) 1990-11-23 1992-06-11 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
JPH06508022A (ja) 1991-02-21 1994-09-14 ギリアド　サイエンシズ，インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993009127A1 (en) 1991-11-07 1993-05-13 Gilead Sciences, Inc. Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
ATE226093T1 (de) 1991-11-26 2002-11-15 Isis Pharmaceuticals Inc Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
WO1993012135A1 (en) 1991-12-12 1993-06-24 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5336615A (en) 1992-01-06 1994-08-09 Yale University Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity
JPH05295017A (ja) * 1992-04-21 1993-11-09 Dai Ichi Kogyo Seiyaku Co Ltd カルバメート基を有する共重合体、その製造方法及び該共重合体を含有する熱可塑性樹脂組成物
WO1993024507A1 (en) 1992-05-28 1993-12-09 Gilead Sciences, Inc. Conformationally restrained oligomers containing amide or carbamate linkages for sequence-specific binding
US5817781A (en) 1992-06-01 1998-10-06 Gilead Sciences, Inc. Modified internucleoside linkages (II)
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
EP0648265A4 (en) 1992-06-18 1996-12-04 Genpharm Int PROCESS FOR THE PRODUCTION OF NON-HUMAN TRANSGENIC ANIMALS HAVING AN ARTIFICIAL YEAST CHROMOSOME.
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
RU2123492C1 (ru) * 1993-02-19 1998-12-20 Ниппон Синяку Ко., Лтд Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
JPH09504266A (ja) * 1993-05-24 1997-04-28 スミスクライン・ビーチャム・コーポレイション 血液調節ペプチド

Similar Documents

Publication Publication Date Title
JP2000500033A5 (enExample)
JPH11510317A5 (enExample)
JP2000500445A5 (enExample)
JP2000500440A5 (enExample)
JPH11513378A5 (enExample)
JPH11512785A5 (enExample)
JP2000500627A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500406A5 (enExample)
JP2001519678A5 (enExample)
JP2000500115A5 (enExample)
JP2000500322A5 (enExample)
JPH11506914A5 (enExample)
JPH11507352A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JP2000500226A5 (enExample)
JP2000500051A5 (enExample)
JP2000500397A5 (enExample)
JP2000500407A5 (enExample)
JP2000500019A5 (enExample)
JP2000500166A5 (enExample)
JP2000500125A5 (enExample)
JP2000500044A5 (enExample)